Study of the Effect of SR57667B on 18F-Dopa PET Imaging in Patients With Parkinson's Disease
Status:
Completed
Trial end date:
2007-03-01
Target enrollment:
Participant gender:
Summary
- The primary objective is to study the effect of SR57667B at the dose of 4 mg/d on
progression of dopaminergic nigro-striatal lesions assessed by 18F-Dopa PET imaging.
- Secondary objectives are to assess the effect of SR57667B on symptomatic decline in
patients with early PD, to assess the safety/tolerability of SR57667B in patients with
early PD and to document plasma concentrations of SR57667 in patients with early PD.